

Thermo Scientific DRI Hydrocodone Assay

Qualitative / Semi-Quantitative Detection of Hydrocodone and its Metabolites

- Specifically detects Hydrocodone and major metabolites
- Qualitative and semi-quantitative
- Superior assay precision
- Excellent correlation to LC-MS/MS
- Liquid ready to use
- Applications available on a range of clinical analyzers



Hydrocodone, a semi-synthetic opioid, is an antitussive (cough suppressant) and narcotic analgesic agent for the treatment of moderate to severe pain. Hydrocodone is the most frequently prescribed opiate in the United States. There are several hundred brand name and generic combinations of hydrocodone products marketed. The most frequently prescribed combination is hydrocodone and acetaminophen (Vicodin®, Lortab®). The 2013 National Survey on Drug Use and Health (NSDUH) reports that 24.4 million people, aged 12 and older, used hydrocodone for nonmedical purposes in the US. Hydrocodone is the most abused prescription drug in the United States.

The Thermo Scientific™ DRI® Hydrocodone Assay is a homogeneous enzyme immunoassay based on the competition of an enzyme glucose-6-phosphate dehydrogenase (G6PDH) labeled drug and the drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the enzyme-labeled drug is bound by the specific antibody and the enzyme activity is inhibited. This phenomenon creates a direct relationship between drug concentration in urine and the enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.

Thermo
SCIENTIFIC

A Thermo Fisher Scientific Brand

Precision

Samples were prepared by spiking hydrocodone into drug free urine at the cutoff (100%), 25%, 50%, and 75% above and below the cutoff and tested in both qualitative and semi-quantitative modes using a Clinical Laboratory and Standards Institute (CLSI) protocol. Results presented to the right were generated by testing all samples in replicates of 2, twice per day for 20 days, total n=80.

Total Precision (n=80)				
Hydrocodone Spike Concentration (ng/mL)	% of Cut-off 300 ng/mL	LC-MS/MS (ng/mL)	Number of Determinations	Immunoassay Results
0	-100%	0	80	80 Neg
75	-75%	87	80	80 Neg
150	-50%	170	80	80 Neg
225	-25%	255	80	80 Neg
300	100%	345	80	46 Neg / 34 Pos (qualitative) 40 Neg / 40 Pos (semi-quantitative)
375	25%	442	80	80 Pos
450	50%	535	80	80 Pos
525	75%	561	80	80 Pos
600	100%	664	80	80 Pos

Accuracy

One hundred patient samples were analyzed by the Thermo Scientific™ DRI® Hydrocodone Assay in both qualitative and semi-quantitative modes and the results were compared to LC-MS/MS. At 300 ng/mL cutoff, the overall concordance between the DRI Hydrocodone Assay and LC-MS/MS was 93%.

Qualitative/ Semi-Quantitative	LC-MS/ MS		
	+	-	
DRI Hydrocodone Assay	+	49	6*
	-	1	44

* 2 samples have oxycodone > 37,000 ng/mL

Cross-reactivity

The cross-reactivity of hydrocodone and its metabolites was evaluated by adding known amounts of each metabolite to drug-free urine. As indicated by the results in the table below, hydromorphone and hydromorphone glucuronide exhibited >100% cross reactivity. Norhydromorphone and 6-Hydrocodol showed significantly less cross reactivity.

Analyte	Concentration tested (ng/mL)	% Cross-reactivity
Hydrocodone	300	102
Hydromorphone	250	122
Hydromorphone Glucuronide	250	122
6-Hydrocodol (Dihydrocodeine)	11,000	2.7
Norhydrocodone	10,000	3.1

The potential cross-reactivity posed by drugs commonly coadministered with hydrocodone was evaluated by adding each substance to drug-free urine at the concentration indicated.

thermoscientific.com/diagnostics

© 2015 Thermo Fisher Scientific Inc. All rights reserved. Vicodin trademark owner - Abbvie Inc. Corporation Delaware 1 N. Waukegan Road Dept. V377, Bldg. Ap34 North Chicago, Illinois 60064. Lortab trademark owner - UCB Pharma Inc. Corporation Delaware 1950 Lake Park Drive, Atlanta, Georgia 30080. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries.

Diagnostics

USA

46500 Kato Road
Fremont, CA 94538 USA
Tel. 800-232-3342 / + 1 510-979-5000
sales.diagnostics.fmt@thermofisher.com

Asia Pacific

Fax: +65 6896 2147
cdd.asia.info2@thermofisher.com

Australia

Tel. + 61 1800 333 110
auinfo@thermofisher.com

Belgium Netherlands & Luxembourg

Tel. + 31 76 579 5555
Info.benelux.cdd@thermofisher.com

Canada

Tel. 905-286-4290
CDD.Canada@thermofisher.com

China

Tel. + 86 800 810 5118
sales.china@thermofisher.com

France

Tel. + 33 (0) 1 40 86 65 00
cdx.fr.info@thermofisher.com

Germany

Tel. + 49 (0) 851 886 890
cdx.de.info@thermofisher.com

Hong Kong

Tel. + 852 28854613
sales.hk@thermofisher.com

Japan

Tel. + 81 (0)120-147-075
JPYOK-CDD.QC@thermofisher.com

New Zealand

Tel. + 61 0800933 966
nzinfo@thermofisher.co.nz

Nordic

Tel. + 46 8 594 691 30
info.nordic.cdd@thermofisher.com

Spain, Portugal & Italy

Tel. + 34 93589 8338
cdx.es.info@thermofisher.com

Switzerland & Austria

Tel. + 41 26 663 86 70
cdx.ch.info@thermofisher.com

United Kingdom & Ireland

Tel. + 44 1442 868 940
cdx.UK.info@thermofisher.com

For Countries Not Listed

distributor.cdd@thermofisher.com